Date:3/5/2010

MISSISSAUGA, ON, March 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX:YM), today announced that it is raising approximately US$15 million in a "registered direct" offering of units at a price of US$1.20 per unit. Each unit consists of one common share and one half of one common share purchase warrant. Each whole warrant entitles the holder to acquire one common share at a price of US$1.60 commencing six months from closing for a period of five years from closing. Roth Capital Partners, LLC, served as lead placement agent. Bloom Burton & Co. Inc., Griffin Securities, Inc. and Haywood Securities Inc. served as co-placement agents for the transaction.

The funds will be used principally to fund YM's drug development activities and for general corporate purposes.

The transaction is expected to close on or about March 10, 2010, pending stock exchange app
'/>"/>

SOURCE YM BioSciences Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
2. TEI Biosciences PriMatrix(TM) Awarded Seal of Approval by American Podiatric Medical Association
3. YM BioSciences presents CYT387 and CYT997 data at international cancer conference
4. YM BioSciences granted two US patents for AeroLEF(R)
5. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
6. YM BioSciences reports second quarter 2010 operational and financial results
7. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
8. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
9. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
10. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
11. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA